- Home
- MUX vs ABUS Comparison
MUX vs ABUS Comparison
Compare MUX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUX
- ABUS
- Stock Information
- Founded
- MUX 1979
- ABUS 2005
- Country
- MUX Canada
- ABUS United States
- Employees
- MUX N/A
- ABUS N/A
- Industry
- MUX Precious Metals
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- MUX Basic Materials
- ABUS Health Care
- Exchange
- MUX Nasdaq
- ABUS Nasdaq
- Market Cap
- MUX 936.8M
- ABUS 906.7M
- IPO Year
- MUX N/A
- ABUS N/A
- Fundamental
- Price
- MUX $16.12
- ABUS $4.34
- Analyst Decision
- MUX Strong Buy
- ABUS Strong Buy
- Analyst Count
- MUX 4
- ABUS 2
- Target Price
- MUX $19.63
- ABUS $5.00
- AVG Volume (30 Days)
- MUX 1.3M
- ABUS 1.1M
- Earning Date
- MUX 11-06-2025
- ABUS 11-13-2025
- Dividend Yield
- MUX N/A
- ABUS N/A
- EPS Growth
- MUX N/A
- ABUS N/A
- EPS
- MUX N/A
- ABUS N/A
- Revenue
- MUX $166,453,000.00
- ABUS $14,606,000.00
- Revenue This Year
- MUX $12.57
- ABUS $138.02
- Revenue Next Year
- MUX $23.31
- ABUS N/A
- P/E Ratio
- MUX N/A
- ABUS N/A
- Revenue Growth
- MUX N/A
- ABUS 116.64
- 52 Week Low
- MUX $6.38
- ABUS $2.71
- 52 Week High
- MUX $24.88
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- MUX 41.07
- ABUS 45.67
- Support Level
- MUX $15.92
- ABUS $4.08
- Resistance Level
- MUX $18.46
- ABUS $4.87
- Average True Range (ATR)
- MUX 1.02
- ABUS 0.23
- MACD
- MUX -0.18
- ABUS -0.05
- Stochastic Oscillator
- MUX 31.73
- ABUS 32.28
About MUX McEwen Mining Inc.
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.